The utility of liver biopsy in 2020
- PMID: 32097176
- PMCID: PMC10874678
- DOI: 10.1097/MOG.0000000000000621
The utility of liver biopsy in 2020
Abstract
Purpose of review: Over the past decade, imaging modalities and serological tests have emerged as important tools in the evaluation of liver diseases, in many cases supplanting the use of liver biopsy and histological examination. Nonetheless, the accuracy and diagnostic value of these methods may not always be conclusive and the assessment of liver histology often remains the gold standard for diagnostic evaluation. The purpose of this review is to summarize the current role of liver biopsy in contemporary hepatology practice.
Recent findings: Technical factors were found to influence the diagnostic value of liver biopsy and histological examination of the liver, including specimen number and size (preferably ≥3 nonfragmented specimens of >20 mm in length), needle diameter (1.6 mm Menghini), number of passes (mean 2.5), imaging-guidance, and operator experience. Liver biopsy was demonstrated to be diagnostically valuable in the evaluation of persistently abnormal liver tests of unclear cause, with histology pointing to a specific diagnosis in 84% of patients. Although coagulation abnormalities continue to be an important concern when performing liver biopsy, their influence on complication risk remains unclear. Implementation of less stringent preprocedural coagulation thresholds decreased preprocedural transfusions without increasing the bleeding rate. Serious complications associated with percutaneous liver-biopsy (PLB) and transjugular liver-biopsy are similar, but pain appears to be more common with PLB.
Summary: Histopathological evaluation continues to be fundamentally important in assessing hepatic disease, and liver histology remains the most accurate approach to assess fibrosis and assign prognosis.
Conflict of interest statement
Conflicts of interest
There are no conflicts of interest.
References
-
- Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009; 49:1017–1044. - PubMed
-
- Cadranel JF, Nousbaum JB, Gouillou M, Hanslik B. Major changes in the number and indications of liver biopsy for chronic liver diseases over one decade in France. Eur J Gastroenterol Hepatol 2016; 28:e26–e32. - PubMed
-
- Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006; 43(2 Suppl 1):S113–S120. - PubMed
-
- Bravo AA, Sheth SG, Chopra S. Liver biopsy. New Engl J Med 2001; 344:495–500. - PubMed
-
- Tapper EB, Lok ASF. Use of liver imaging and biopsy in clinical practice. New Engl J Med 2017; 377:756–768. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous